Nautilus Historical Income Statement

NAUT Stock

USD 2.24 0.06 2.61%

Historical analysis of Nautilus Biotechnology income statement accounts such as Other Operating Expenses of 58.2 M can show how well Nautilus Biotechnology performed in making a profits. Evaluating Nautilus Biotechnology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Nautilus Biotechnology's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Nautilus Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Nautilus Biotechnology is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nautilus Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.

About Nautilus Income Statement Analysis

Nautilus Biotechnology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Nautilus Biotechnology shareholders. The income statement also shows Nautilus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Nautilus Biotechnology Income Statement Chart

At this time, Nautilus Biotechnology's Interest Expense is comparatively stable compared to the past year. Interest Income is likely to gain to about 13 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.8 M in 2024.

Selling General Administrative Other Operating Expenses Total Operating Expenses Total Other Income Expense Net Net Income Applicable To Common Shares

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Nautilus Biotechnology. It is also known as Nautilus Biotechnology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Most accounts from Nautilus Biotechnology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Nautilus Biotechnology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nautilus Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.At this time, Nautilus Biotechnology's Interest Expense is comparatively stable compared to the past year. Interest Income is likely to gain to about 13 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.8 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	2.8M	3.4M	5.0M	3.8M
Cost Of Revenue	2.8M	3.4M	5.7M	3.9M

Reconciled Depreciation Cost Of Revenue

Nautilus Biotechnology income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Research Development	Interest Income	Gross Profit	Net Income From Continuing Ops	Cost Of Revenue	Reconciled Depreciation	Income Tax Expense	Net Interest Income	Non Operating Income Net Other	Selling And Marketing Expenses
Depreciation And Amortization		0.99	0.89	-0.86	-0.86	1.0	0.89	1.0	1.0	1.0	-0.79	-0.58	0.59	0.73	-0.59	-0.62	-0.6	-0.57	0.61	0.45
Selling General Administrative	0.99		0.95	-0.92	-0.93	0.98	0.95	0.98	0.99	0.98	-0.69	-0.48	0.49	0.62	-0.48	-0.51	-0.49	-0.46	0.51	0.37
Other Operating Expenses	0.89	0.95		-0.99	-0.99	0.86	1.0	0.87	0.89	0.87	-0.42	-0.24	0.25	0.35	-0.22	-0.24	-0.22	-0.2	0.25	0.2
Operating Income	-0.86	-0.92	-0.99		1.0	-0.83	-0.99	-0.83	-0.86	-0.83	0.39	0.14	-0.15	-0.28	0.17	0.19	0.2	0.15	-0.18	-0.07
Ebit	-0.86	-0.93	-0.99	1.0		-0.83	-0.99	-0.84	-0.87	-0.84	0.4	0.15	-0.15	-0.3	0.18	0.19	0.22	0.16	-0.2	-0.07
Ebitda	1.0	0.98	0.86	-0.83	-0.83		0.86	1.0	1.0	1.0	-0.82	-0.62	0.63	0.77	-0.62	-0.65	-0.63	-0.6	0.65	0.48
Total Operating Expenses	0.89	0.95	1.0	-0.99	-0.99	0.86		0.87	0.89	0.87	-0.42	-0.24	0.25	0.35	-0.22	-0.24	-0.22	-0.2	0.25	0.2
Income Before Tax	1.0	0.98	0.87	-0.83	-0.84	1.0	0.87		1.0	1.0	-0.81	-0.61	0.62	0.76	-0.61	-0.64	-0.63	-0.6	0.64	0.47
Total Other Income Expense Net	1.0	0.99	0.89	-0.86	-0.87	1.0	0.89	1.0		1.0	-0.78	-0.58	0.58	0.73	-0.58	-0.61	-0.59	-0.56	0.61	0.45
Net Income	1.0	0.98	0.87	-0.83	-0.84	1.0	0.87	1.0	1.0		-0.81	-0.61	0.62	0.76	-0.61	-0.64	-0.63	-0.6	0.64	0.47
Research Development	-0.79	-0.69	-0.42	0.39	0.4	-0.82	-0.42	-0.81	-0.78	-0.81		0.8	-0.8	-0.95	0.87	0.9	0.9	0.85	-0.85	-0.55
Interest Income	-0.58	-0.48	-0.24	0.14	0.15	-0.62	-0.24	-0.61	-0.58	-0.61	0.8		-0.99	-0.86	0.92	0.93	0.84	0.94	-0.93	-0.9
Gross Profit	0.59	0.49	0.25	-0.15	-0.15	0.63	0.25	0.62	0.58	0.62	-0.8	-0.99		0.86	-0.91	-0.92	-0.79	-0.92	0.88	0.93
Net Income From Continuing Ops	0.73	0.62	0.35	-0.28	-0.3	0.77	0.35	0.76	0.73	0.76	-0.95	-0.86	0.86		-0.83	-0.87	-0.85	-0.82	0.89	0.69
Cost Of Revenue	-0.59	-0.48	-0.22	0.17	0.18	-0.62	-0.22	-0.61	-0.58	-0.61	0.87	0.92	-0.91	-0.83		1.0	0.91	0.98	-0.86	-0.71
Reconciled Depreciation	-0.62	-0.51	-0.24	0.19	0.19	-0.65	-0.24	-0.64	-0.61	-0.64	0.9	0.93	-0.92	-0.87	1.0		0.93	0.99	-0.89	-0.72
Income Tax Expense	-0.6	-0.49	-0.22	0.2	0.22	-0.63	-0.22	-0.63	-0.59	-0.63	0.9	0.84	-0.79	-0.85	0.91	0.93		0.95	-0.93	-0.51
Net Interest Income	-0.57	-0.46	-0.2	0.15	0.16	-0.6	-0.2	-0.6	-0.56	-0.6	0.85	0.94	-0.92	-0.82	0.98	0.99	0.95		-0.92	-0.72
Non Operating Income Net Other	0.61	0.51	0.25	-0.18	-0.2	0.65	0.25	0.64	0.61	0.64	-0.85	-0.93	0.88	0.89	-0.86	-0.89	-0.93	-0.92		0.72
Selling And Marketing Expenses	0.45	0.37	0.2	-0.07	-0.07	0.48	0.2	0.47	0.45	0.47	-0.55	-0.9	0.93	0.69	-0.71	-0.72	-0.51	-0.72	0.72

Click cells to compare fundamentals

Nautilus Biotechnology Account Relationship Matchups

Nautilus Biotechnology income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	548.0	2.3M	2.8M	3.4M	1.8M	1.8M
Selling General Administrative	1.6K	3.3M	21.1M	25.9M	28.9M	25.5M
Other Operating Expenses	9.6K	15.7M	50.5M	63.6M	76.2M	58.2M
Operating Income	(10.1K)	(15.7M)	(50.5M)	(63.6M)	(76.2M)	(80.0M)
Ebit	(10.1K)	(15.6M)	(50.3M)	(57.9M)	(76.2M)	(80.0M)
Ebitda	(9.6K)	(13.3M)	(47.5M)	(54.5M)	(74.3M)	(70.6M)
Total Operating Expenses	9.6K	15.7M	50.5M	63.6M	76.2M	58.2M
Income Before Tax	(9.6K)	(15.6M)	(50.3M)	(57.9M)	(63.7M)	(60.5M)
Total Other Income Expense Net	492.0	125K	183K	5.7M	12.5M	11.9M
Net Income	(9.6K)	(15.6M)	(50.3M)	(63.7M)	(63.7M)	(60.5M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nautilus Historical Income Statement

About Nautilus Income Statement Analysis

Nautilus Biotechnology Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Net Income Applicable To Common Shares

Nautilus Biotechnology income statement Correlations

Nautilus Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Nautilus Biotechnology income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Nautilus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation And Amortization	Interest Expense
Selling General Administrative	Other Operating Expenses
Operating Income	Ebit
Ebitda	Total Operating Expenses
Income Before Tax	Total Other Income Expense Net
Net Income	Research Development
Net Income Applicable To Common Shares	Interest Income
Total Revenue	Gross Profit
Net Income From Continuing Ops	Cost Of Revenue
Reconciled Depreciation	Income Tax Expense
Net Interest Income	Non Operating Income Net Other
Selling And Marketing Expenses

Ebitda	+ 1.0	Depreciation And Amortization
Income Before Tax	+ 1.0	Depreciation And Amortization
Total Other Income Expense Net	+ 1.0	Depreciation And Amortization
Net Income	+ 1.0	Depreciation And Amortization
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income

Gross Profit	- 0.99	Interest Income
Total Operating Expenses	- 0.99	Ebit
Total Operating Expenses	- 0.99	Operating Income
Ebit	- 0.99	Other Operating Expenses
Operating Income	- 0.99	Other Operating Expenses
Net Income From Continuing Ops	- 0.95	Research Development